These are publications from work undertaken by Frontier Science (Scotland).

D Fumagalli;  D Venet; M Ignatiadis; H A Azim Jr; M Maetens; F Rothé; R Salgado; I Bradbury; L Pusztai; N Harbeck; H Gomez; T W Chang; M Coccia-Portugal; S Di Cosimo; E. de Azambuja; L de la Pena; P Nuciforo; J C Brase; J Huober; J Baselga; M. Piccart; S Loi; C Sotiriou;  2017

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial

JAMA Oncol,  Pages 227-234, 3(2) doi:10.1001/jamaoncol.2016.3824

E McFadden;  2016

Data Management and Coordination

Wiley StatsRef: Statistics Reference online,  1-14 doi:10.1002/9781118445112.stat04933.pub2

I Gingras;  E Holmes; E. de Azambuja; D H A Nguyen; M Izquierdo; J A Zujewski; M Inbar; B Naume; G Tomasello; J Gralow; AC Wolff; L Harris; M Gnant; A Moreno-Aspitia; M. Piccart; H. A. Azim Jr;  2017

Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis from the ALTTO Trial

Journal of the National Cancer Institute,  Volume 109, Issue 8, doi: 10.1093/jnci/djw331

W Shi;  T Jiang; P Nuciforo; C Hatzis; E Holmes; N Harbeck; C Sotiriou; L Peña; S Loi; D Rosa; S Chia; A Wardley; T Ueno; J Rossari; H. Eidtmann; A Armour; M Piccart-Gebhart; D L Rimm; J Baselga; L Pusztai;  2017

Pathway level alterations rather than mutations in single genes predict response to HER2 targeted therapies in the neo-ALTTO trial

Annals of Oncology,  Volume 28, Issue 1, p128-135, doi:10.1093/annonc/mdw434

D Cameron;  M Piccart-Gebhart; RD Gelber; M Procter; A Goldhirsch; E. de Azambuja; G Castro Jr; M Untch; I Smith; L Gianni; J Baselga; N Al-Sakaff; S Laver; E McFadden; B Leyland-Jones; R Bell; M Dowsett; C Jackisch;  March 25, 2017

11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial,  Volume 389, Issue 10075, pp. 1195-1205, doi:10.1016/S0140-6736(16)32616-2

S Di Cosimo;  C Campbell; H A Hazim; G Curigliano; R Crescenzo; L de la Pena; M Piccart-Gebhart; H. Eidtmann; J Baselga; E. de Azambuja;  2016

Breast ultrasound and mammography and response to neoadjuvant lapatinib, trastuzumab and their combination in HER2 positive breast cancer: Results from Neo-ALTTO (BIG 1-06)

Cancer Research,  Volume 76, Issue 4, doi:10.1158/1538-7445.SABCS15-P6-01-04

E McFadden;  S Bashir; S Canham; J Darbyshire; P Davidson; S Day; S Emery; J Pater; S Rudkin; M Stead; J Brown;  2015

The impact of registration of clinical trials units: the UK experience

Clinical Trials,  Volume 12, Issue 2, Pages 166-173, doi:10.1177/1740774514561242

O Metzger-Filho;  E. de Azambuja; M Procter; M Krieguer; I Smith; J Baselga; D Cameron; M Untch; C Jackisch; R Bell; L Gianni; A Goldhirsch; M. Piccart; RD Gelber; HERA Study Team;  2016

Trastuzumab Re-Treatment Following Adjuvant Trastuzumab and the Importance of Distant Disease-Free Interval: the HERA Trial Experience

Breast Cancer Research and Treatment,  Volume 155, Issue 1, Pages 127-132,doi: 10.1007%2Fs10549-015-3656-0

A Goldhirsch;  RD Gelber; M Piccart-Gebhart; E. de Azambuja; M Procter; T M Suter; C Jackisch; H A Weber; D Heinzmann; L D Lago; E McFadden; M Dowsett; M Untch; L Gianni; R Bell; A Vindevoghel; M Andersson; C Köhne; D Cameron;  2013

2 Years Versus 1 Year of Adjuvant Trastuzumab for HER2-Positive Breast Cancer (HERA): an Open-Label, Randomised Controlled Trial

The Lancet,  Volume 382, Issue 9897, Pages 1021-1028, doi: 10.1016/S0140-6736(13)61094-6

O Metzger-Filho;  M Procter; E. de Azambuja; B Leyland-Jones; RD Gelber; M Dowsett; S Loi; K S Saini; D Cameron; M Untch; I Smith; L Gianni; J Baselga; C Jackisch; R Bell; C Sotiriou; G Viale; M Piccart-Gebhart;  2013

Magnitude of Trastuzumab benefit in patients with HER2 positive, invasive lobular breast carcinoma: results from the HERA trial

Journal of Clinical Oncology,  Volume 31, Issue 16, Pages 1954-1960, doi: 10.1200/JCO.2012.46.2440